PTCE - Patient Safety and Quality Assurance (23.75% of the exam) - Section 3.1

Identify high-alert and high-risk medications and look-alike/sound-alike (LASA) medication pairs.

Identify ISMP high-alert and high-risk medications that carry a heightened potential for patient harm, and recognise common look-alike/sound-alike (LASA) drug pairs. Apply Tall Man lettering and physical inventory separation as strategies to reduce LASA-related dispensing errors.

High-alert medicationLASAISMPTall Man lettering

Practice question for this objective

Free samplePatient Safety and Quality Assurancemedium

A technician at Hollowmere Pharmacy receives an electronic prescription for a patient named Cassian Delgado that the system displays in plain lower case as celecoxib. The pharmacy's safety committee wants to reduce mix-ups with the sound-alike products citalopram and Celexa during dispensing. Which committee decision best targets the cause of this particular confusion?

AShorten the patient counselling session so the pharmacist can verify more prescriptions each hour
BReassign all data entry for these products to the most senior technician on each shift
CApply Tall Man lettering to the confused names on shelf labels and screens, such as celeCOXIB and citalopram Correct
DPrint every prescription in a larger font so the drug name is easier to read at a glance

Tall Man lettering on confused drug names addresses the visual cause of look-alike and sound-alike dispensing errors. Look-alike and sound-alike confusions persist when similar names are displayed in uniform lower case, so the targeted control is Tall Man lettering, which capitalises the differing letters to force the eye to register the distinction at every point a name appears, rather than depending on individual vigilance or font size.

Why A is wrong: Reducing counselling time increases throughput but removes a final chance to catch an error and does nothing to address the name similarity that triggers the confusion.

Why B is wrong: Seniority does not immunise a person against a look-alike name displayed in plain text, so this relies on individual vigilance rather than fixing the systemic display problem.

Why C is correct: Applying Tall Man lettering to the differing portions of confused names on labels and screens is the targeted system control that visually breaks up sound-alike and look-alike names at the point of dispensing.

Why D is wrong: A larger font improves legibility of a single name but makes a misread word only more prominent, since it does not distinguish names that look and sound alike in the first place.

See more PTCE practice questions, answers explained.

Exam traps in Patient Safety and Quality Assurance

Answers that look right on this material and are not. Each one is a distractor from a different question in the PTCE bank for this domain.

It marks both products as high-alert medicines that require an independent double check before dispensing.
Why it is wrong: High-alert status is real and may apply to some drugs, but mixed-case lettering is not how high-alert items are flagged; the capitalisation here is solely to distinguish similar names.
Adding a leading zero to the dose so the strength reads 025 mg on both shelf labels
Why it is wrong: Leading zeros are placed before a decimal point for doses below one, such as 0.5 mg, to prevent tenfold dose misreads; they do nothing to separate two distinct drug names and 025 mg is not a valid format.
It replaces brand names with generic names so that staff always read from a single naming standard.
Why it is wrong: This confuses Tall Man lettering with generic substitution. Tall Man lettering keeps the same drug name; it does not switch between brand and generic naming, so it is wrong.

Examworthy is not affiliated with or endorsed by PTCB. Original, blueprint-aligned practice material only.